Many aspects of stroke trials conducted in the prehospital setting differ from traditional hospital-based trials. Enrollment yield and the reasons for screen failure may be expected to be different for prehospital than for Emergency Department acute stroke trials.
I n acute focal ischemic and hemorrhagic stroke, neuronal injury progresses rapidly after first onset of ischemia or hemorrhage. 1 Stroke trialists are beginning to test novel therapies in the prehospital setting, evaluating neuroprotective agents that may be administered by paramedics without requiring brain imaging and thrombolytic treatment ordered by physicians in ambulances equipped with mobile computed tomographic scanners.
Methods
FAST-MAG was a pivotal, placebo-controlled, randomized clinical trial of field-initiated magnesium sulfate in acute stroke with enrollment taking place in Los Angeles and Orange Counties in the United States between January 2005 and December 2012. 3 The great preponderance (>98%) of patients in FAST-MAG were enrolled using explicit, written, informed consent procedures, with a small proportion enrolled using exception from informed consent in emergency circumstances.
The FAST-MAG trial used a 2-stage screening process for patient enrollment. [3] [4] [5] [6] In the first step, paramedics identified potentially study eligible patients and called to the responding physician. In the second step, physician-investigators performed the final study eligibility determination, based on paramedic report and discussion with the patient or on-scene legally authorized representatives (LARs).
Initially, in addition to the modified Los Angeles Prehospital Stroke Screen, 4 inclusion criteria were developed with evaluation of all 10 study exclusion criteria left for the phone-enrolling physician-investigator. 4, 5 During the course of the study, 3 revisions to the screening form were made, adding several exclusion criteria elements for paramedic performance ( Table 1) . Two of these revisions aimed to reduce nonenrollment calls, and exclusion of blood pressure >220 mm Hg aimed to reduce the proportion of hemorrhage patients enrolled because the study hypothesized treatment benefit in ischemia and neutral effect in hemorrhage.
For all calls from paramedics not resulting in an enrollment, physician-investigators recorded the reason for nonenrollment. Details of methods and main results of the trial have been reported previously with the final paramedic screening form and exclusion criteria.
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Results
During the 8-year study period, 4458 potential subjects were screened by enrolling physicians from paramedic phone calls. Among the 315 ambulances that participated in the trial, the median duration of active screening in the trial was 64 months (interquartile range, 24-81). Accordingly, the average ambulance made 1 screening call to an enrolling physician every 135.7 days and yielded 1 study enrollment every 355.7 days. Among these, 1700 patients (38.1%) were enrolled.
Among enrolled patients, final diagnoses of the qualifying event were cerebral ischemia in 73.3%, intracranial hemorrhage in 22.8%, and cerebrovascular disease mimic in 3.9%.
Among 2758 nonenrolled patients (61.9%), a total of 3140 reasons for nonenrollment were documented ( Table 2 ). The most common reasons for nonenrollment were being >2 hours from last known well time (17.2%), having a preexisting condition causing disability (16.1%), and patient being not competent with no LARs on-scene to provide consent (9.5%).
Aspects of the presenting neurological deficit making the diagnosis of acute stroke insecure accounted for 29.8% of the nonenrollment reasons, including last known well time >2 hours (17.2%), rapidly improving deficit (7.6%), absence of any arm or face motor deficit (2.8%), presence of bilateral weakness (1.5%), and coma (0.7%).
Barriers to completion of prehospital phone informed consent process accounted for 20.8% of the nonenrollment reasons, including the absence of a consent provider on-scene (9.5%), patient not fluent in the English or Spanish languages (4.3%), phone connection difficulties (3.2%), patient or LARs too hard of hearing to understand physician-investigator over the phone (1.4%), etc ( Table 2) .
Informed nonconsent (informed decision to decline participation in the study) accounted for 6.7% of nonenrollment reasons, including declinations by patients (3.8%) and declinations by LARs (2.9%).
Changes in the screening form were not associated with a reduction, and actually associated with an increase, in the proportion of calls that were nonenrollments (P=0.009; Table 1 ). Before addition of initial systolic blood pressure of >220 mm Hg exclusion criteria, the rate of hemorrhage enrollment was 24.3% (190/782) and after 21.5% (197/918), (P=0.16). There was a correlation between calendar date of enrollment (by quarter) and rate of hemorrhage enrollment was 0.50 (P=0.004, Spearman test for correlation; Table I in the onlineonly Data Supplement).
Discussion
This study's findings highlight that the 2-stage screening method in FAST-MAG, involving paramedics and then physician-investigators, was important to assure stringent patient selection. Overall, the low rate of mimics (3.9%) entered into FAST-MAG using the 2-stage screening process contrasts favorable with the higher rates of mimics enrolled in smaller prehospital stroke trials using 1 stage, paramedic screening (7%-13%), [7] [8] [9] or less formal 2-stage processes (24%). 10 Time since onset longer than target, an exclusion criteria available to paramedics, was the most common reason for physician exclusion of patients. Enrolling physicians were able to exclude cases where there was uncertainty of onset of unfamiliarity with the strict definition of last known well time. It is possible that paramedics erred on the side of calling physicians in cases with uncertain time of onset, knowing that the trial would be more greatly set back by missing an eligible patient than by physician screening of an uncertainly eligible patient. Disability before onset of the current stroke was the second most common reason for nonenrollment, and it is a difficult variable to assess for individuals who are not experienced stroke trialists.
The enrollment yield of this prehospital study (38.1%) is similar to that (37.3%) of a recent multicenter neuroprotective trial using in-hospital recruitment, 11 but the spectrum of reasons for nonenrollment differ. First, noncompetent patients were frequently not accompanied by an LARs in the field who could provide consent. The longer enrollment time window in Emergency Department-based trials often permits LARs to arrive or be contacted by phone. Exception from informed consent enrolling was permitted at most sites when no LARs was available, but the requirement of a person who knew the patients well and could provide a reliable prestroke medical history limited its enrollment yield. Second, cell phone connection difficulties did occur as a reason for nonenrollment in FAST-MAG, but at a low (3%) rate, indicating that incorporation of cell phone processes into enrollment mechanisms is feasible in the current cellular broadband environment. Third, noncognitive communication barriers included presbyacusis, preventing consent providers from hearing physicians over the phone, and severe dysarthria, preventing physician-investigators from understanding patients. These would usually be able to be overcome with more time to interact and the availability of nonverbal modes of complementary messaging with in person-consenting in hospital. Because the prehospital setting might be inherently coercive, and patients and LARs in the prehospital setting are not in a position to make an unforced decision, the informed declination rate would be lower in a prehospital than a hospital-based hyperacute trial. However, the rate of declination in FAST-MAG was substantially higher (6.7% of nonenrollment reasons) than that in contemporaneous trials of in-hospital neuroprotective (1.9%) and endovascular (2.5%) acute stroke treatment. 11, 12 These findings suggest that the prehospital setting and brief time window for decision-making actually somewhat influenced consent providers against rather than toward participation.
Screening form changes to reduce screen failure call were paradoxically associated with an increase, rather than decrease, in nonenrollment calls. This increase probably reflects the countervailing influences of (1) increased paramedic awareness of and enthusiasm for the trial as the study progressed, leading to call even when exclusion criteria were present just to be sure not to miss an enrollable patient, and (2) more stringent application of exclusion criteria by physician-investigator as the study progressed to enroll the most informative cohort once it was clear that study would be proceeding to completion.
Also during the course of the trial, a goal was to reduce the rate of enrollment of hemorrhagic versus patients with ischemic stroke because the study hypothesized treatment benefit in ischemia and neutral effect in hemorrhage. Exclusion of the cases with systolic blood pressure of >220 mm Hg on first measurement by paramedics was associated with a nominal decrease in hemorrhage enrollments that did not reach statistical significance. However, during the entire course of the study, a statistical significant decline in hemorrhage enrollments did occur, probably as a combined result of the screening form change and of increased enrolling-investigator stringency in assessing exclusion criteria in patients with presentations suggestive of hemorrhage.
The findings of this study will be useful to planning of future prehospital stroke trials. Studies of paramedic-delivered prehospital therapies for acute stroke should take into account that the enrollment yield from paramedic calls to off-scene enrolling physicians will be ≈40%.
Sources of Funding
This study was supported by an Award from the National Institutes of Health (NIH-NINDS U01 NS 44364).
Disclosures
None. 
Table 2. General Enrollment Yield and Reasons of Exclusion
